Prothena Corp Public (PRTA) Free Cash Flow (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Free Cash Flow of $28.9 million for Q1 2026, up 154.07% year-over-year from $11.4 million in Q1 2025, and up 223.87% quarter-over-quarter from -$23.3 million in Q4 2025.
Powered by 
Analysis
Prothena Corp Public (PRTA) Free Cash Flow (2012 - 2026) Analysis & Trends
Prothena Corp Public's Free Cash Flow history runs 15 years deep, the most recent figure standing at $28.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 154.07% year-over-year to $28.9 million; the TTM figure through Mar 2026 stood at -$81.4 million (up 37.64% YoY), while the FY2025 annual figure was -$163.7 million, down 8.89% from the prior year.
- Free Cash Flow for Q1 2026 stood at $28.9 million, up from -$23.3 million in the prior quarter.
- The five-year high for Free Cash Flow was $28.9 million in Q1 2026, with the low at -$73.2 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$40.6 million (2025), against an average of -$31.2 million.
- The sharpest annual moves came in 2023 and 2026: Free Cash Flow tumbled 925.69% in 2023, then surged 154.07% in 2026.
- Prothena Corp Public's Free Cash Flow stood at -$5.1 million in 2022, then sank by 925.69% to -$52.6 million in 2023, then increased by 9.07% to -$47.8 million in 2024, then surged by 51.25% to -$23.3 million in 2025, then surged by 223.87% to $28.9 million in 2026.
- Business Quant data shows PRTA's Free Cash Flow at $28.9 million in Q1 2026, -$23.3 million in Q4 2025, and -$40.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Prothena Corp Public | 507.63 Mn | 219.43 Mn | - | -25.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.70 Mn |
| Mar 31, 2026 | 28.88 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -40.58 Mn |
| Jun 30, 2025 | -46.43 Mn |
| Mar 31, 2025 | -53.41 Mn |
| Dec 31, 2024 | -47.82 Mn |
| Sep 30, 2024 | -45.20 Mn |
| Jun 30, 2024 | 15.82 Mn |
| Mar 31, 2024 | -73.15 Mn |
| Dec 31, 2023 | -52.59 Mn |
| Sep 30, 2023 | 9.08 Mn |
| Jun 30, 2023 | -45.70 Mn |
| Mar 31, 2023 | -47.51 Mn |
| Dec 31, 2022 | -5.13 Mn |
| Sep 30, 2022 | -31.30 Mn |
| Jun 30, 2022 | -35.42 Mn |
| Mar 31, 2022 | -37.44 Mn |
| Dec 31, 2021 | -22.78 Mn |
| Sep 30, 2021 | 111.90 Mn |